Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07748624 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Trial sites expanded: 0 → 3 locations · Completion date: Apr 21, 2031 to Apr 15, 2031 · Eligibility criteria expanded, about 14 words · 1 more Show 4 more changesShow less
    • Trial sites expanded: 0 → 3 locations
    • Completion date: Apr 21, 2031 to Apr 15, 2031
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints: details revised at 1 of 9 entries
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
555 trials monitored
See 31 trials at risk
The purpose of this study is to evaluate clinical efficacy and safety of arumakimig (MAS825) compared to placebo in patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) syndrome. In addition, the study will evaluate the long-term efficacy, safety and tolerability of arumakimig in this population.
Trial Details
NCT Number NCT07748624
Lead Sponsor Novartis Pharmaceuticals
Conditions VEXAS Syndrome
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov